Patents by Inventor Jun-ichi Endoh

Jun-ichi Endoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amide derivative and use thereof as medicine
    Patent number: 8816079
    Abstract: Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: August 26, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kazuhiro Maeda, Jun-ichi Endoh, Akiko Tarao, Kaoru Tashiro, Seigo Ishibuchi, Hidemasa Hikawa
  • NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE
    Publication number: 20130040930
    Abstract: Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: April 27, 2011
    Publication date: February 14, 2013
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kazuhiro Maeda, Jun-ichi Endoh, Akiko Tarao, Kaoru Tashiro, Seigo Ishibuchi, Hidemasa Hikawa
  • Oxazolidinone amide aromatic compounds for supressing MMP-9 production
    Patent number: 8354401
    Abstract: Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: January 15, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Seigo Ishibuchi, Hidemasa Hikawa, Akiko Tarao, Jun-ichi Endoh, Kunitomo Adachi, Kazuhiro Maeda, Kaoru Tashiro
  • NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE
    Publication number: 20110263571
    Abstract: Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.
    Type: Application
    Filed: October 27, 2009
    Publication date: October 27, 2011
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Seigo Ishibuchi, Hidemasa Hikawa, Akiko Tarao, Jun-ichi Endoh, Kunitomo Adachi, Kazuhiro Maeda, Kaoru Tashiro
  • Thienotriazolodiazepine compound and medicinal use thereof
    Patent number: 8044042
    Abstract: A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: October 25, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata
  • NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20100152261
    Abstract: A nitrogen-containing heterocyclic derivative represented by the following general formula (I), or a hydrate or solvate thereof, which has a selective antagonistic action on the muscarinic M3 receptor and causes reduced cardiac side effect and thus is safe, and has superior pharmacological efficacy and prolonged action even by inhalation administration, and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 25, 2006
    Publication date: June 17, 2010
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Hideyuki Aizawa, Makoto Seki, Jun-ichi Endoh, Minoru Tanaka, Naoto Fujie, Osamu Sakuma, Takao Kamahori
  • THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF
    Publication number: 20100041643
    Abstract: [Solving means] A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. [Effect]Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.
    Type: Application
    Filed: May 30, 2006
    Publication date: February 18, 2010
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata